A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
This study wants to understand how long people with a condition called psoriatic arthritis continue to use a medicine called guselkumab. Psoriatic arthritis is a type of arthritis that affects joints, often in people who also have psoriasis, a skin condition. Researchers will observe adults who are already taking guselkumab as part of their usual care. The main goal is to see how many people are still using this medicine after one year. This information helps doctors understand the long-term use and effectiveness of guselkumab in real-world settings rather than in a highly controlled trial environment. It's an observational study, meaning participants are not given new treatments but are monitored on their existing care.
En un coup d'œil
De quoi parle cette étude ?
This study is about a medicine called guselkumab, which is used to treat psoriatic arthritis. Psoriatic arthritis is a condition that causes joint pain, swelling, and stiffness, and it often affects people who also have psoriasis, a skin condition causing red, scaly patches. Guselkumab is one of the treatments available, and this study aims to see how well it works for people in their everyday lives over a year.
The researchers want to find out how many people continue taking guselkumab for at least one year. This is important because it helps doctors understand if the medicine is effective and well-tolerated enough for people to stick with it long-term. This isn't a study where you try a new experimental drug; instead, it observes what happens when people use guselkumab as part of their regular treatment, decided by their doctor.
By collecting this information, doctors can get a clearer picture of how guselkumab is used and how helpful it is for patients with psoriatic arthritis in real-world situations. This kind of research helps improve future treatment plans and advice for people living with this condition.
Points clés
- This study observes how people use guselkumab for psoriatic arthritis over one year.
- It helps doctors understand how well people stick with the treatment in real life.
- You will not receive any new or different treatment than your doctor prescribed.
- Your medical information from routine visits will be used, with your privacy protected.
- Participation will not change your regular medical care or appointments.
Qui peut être éligible ?
To join this study, you must be an adult with a confirmed diagnosis of psoriatic arthritis, meaning a specialist doctor (rheumatologist) has officially diagnosed you. You should be starting guselkumab for your psoriatic arthritis, and it can be your first or one of your first few stronger arthritis medications. Importantly, your doctor must have already decided you need guselkumab as part of your normal care, without the study influencing that decision.
There are also reasons why you might not be able to join. For instance, if you've already tried a very similar type of medicine (called an IL-23 inhibitor) or if you're taking a combination of different strong arthritis medications at the same time. You also can't join if guselkumab isn't suitable for you based on its official guidance, for example, if you have severe allergies to it or a very active infection like tuberculosis.
Finally, if you're already involved in certain other medical studies or have recently tried experimental drugs, you won't be able to participate. You also need to be willing to have your health information collected over time.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Are you an adult with a formal diagnosis of psoriatic arthritis?
- Are you starting treatment with guselkumab for your psoriatic arthritis?
- Has your doctor already decided you should take guselkumab as part of your normal care?
- Are you willing to let your routine health information be used for this study?
- Are you currently NOT taking a mix of several strong arthritis medications at once?
En quoi consiste la participation ?
If you join this study, it's mostly about letting researchers observe your usual medical care. You won't receive different treatments or extra medications than what your doctor has already decided for you. Your rheumatologist will continue to prescribe guselkumab as planned, and you will attend your regular appointments.
The main part of your involvement will be allowing your health information, which is collected during your routine doctor visits, to be used for the study. This data will help researchers understand how long people continue to use guselkumab. The study focuses on a one-year period, tracking how consistently you take your medication. There won't be any additional clinic visits or special tests just for this study; everything will be part of your standard care.
Risques et avantages potentiels
Emplacements (1)
- Hopital Roger Salengro - CHU LilleCode postal vérifiéLille, France· Recrutement
Questions fréquentes
Qu'est-ce que l'arthrite psoriasique ?
It's a type of arthritis that causes joint pain and stiffness, often affecting people who also have the skin condition psoriasis.
What is guselkumab?
It's a medication used to treat psoriatic arthritis.
Will I get different treatment if I join?
No, you will continue with your usual treatment as decided by your doctor; the study just observes it.
Combien de temps vais-je participer à l'étude ?
The study will look at your treatment for one year, but your participation is mainly about allowing your data to be collected during this period.
Est-ce un nouveau médicament ?
No, guselkumab is an approved medicine. This study is about observing its use in real-world settings.
Comment en savoir plus
Study Contact
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.